{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:11Z","timestamp":1786982771080,"version":"build-2736575974"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40266-023-01049-x","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T13:01:27Z","timestamp":1689080487000},"page":"751-761","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Management of Type 2 Diabetes in Frail Older Adults"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5343-9795","authenticated-orcid":false,"given":"Gulistan","family":"Bahat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0994-1152","authenticated-orcid":false,"given":"Serdar","family":"Ozkok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7506-8646","authenticated-orcid":false,"given":"Mirko","family":"Petrovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"key":"1049_CR1","unstructured":"IDF Diabetes Atlas 2021. https:\/\/diabetesatlas.org\/atlas\/tenth-edition\/. Accessed 5 Jan 2023."},{"issue":"1","key":"1049_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13098-020-0523-x","volume":"12","author":"J Shou","year":"2020","unstructured":"Shou J, Chen P-J, Xiao W-H. Mechanism of increased risk of insulin resistance in aging skeletal muscle. Diabetol Metab Syndr. 2020;12(1):14.","journal-title":"Diabetol Metab Syndr"},{"issue":"6","key":"1049_CR3","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s11892-013-0425-5","volume":"13","author":"M Corriere","year":"2013","unstructured":"Corriere M, Rooparinesingh N, Kalyani RR. Epidemiology of diabetes and diabetes complications in the elderly: an emerging public health burden. Curr Diab Rep. 2013;13(6):805\u201313.","journal-title":"Curr Diab Rep"},{"issue":"3","key":"1049_CR4","doi-asserted-by":"publisher","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","volume":"56","author":"LP Fried","year":"2001","unstructured":"Fried LP, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146\u201356.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"9868","key":"1049_CR5","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","volume":"381","author":"A Clegg","year":"2013","unstructured":"Clegg A, et al. Frailty in elderly people. Lancet. 2013;381(9868):752\u201362.","journal-title":"Lancet"},{"issue":"34","key":"1049_CR6","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"issue":"1","key":"1049_CR7","first-page":"S195","volume":"45","author":"ADAPP Committee","year":"2021","unstructured":"Committee ADAPP. Older adults: standards of medical care in diabetes\u20142022. Diabetes Care. 2021;45(1):S195\u2013207.","journal-title":"Diabetes Care"},{"issue":"11","key":"1049_CR8","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386.","journal-title":"Diabetes Care"},{"issue":"33","key":"1049_CR9","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104.","journal-title":"Eur Heart J"},{"issue":"34","key":"1049_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030169","volume":"101","author":"X Wang","year":"2022","unstructured":"Wang X, Hu J, Wu D. Risk factors for frailty in older adults. Medicine (Baltimore). 2022;101(34): e30169.","journal-title":"Medicine (Baltimore)"},{"key":"1049_CR11","doi-asserted-by":"crossref","unstructured":"Abd.Ghafar MZA, et al. Frailty and diabetes in older adults: overview of current controversies and challenges in clinical practice. Front Clin Diabetes Healthc. 2022;3:895313.","DOI":"10.3389\/fcdhc.2022.895313"},{"issue":"3","key":"1049_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2337\/dc22-1728","volume":"46","author":"FR Simpson","year":"2022","unstructured":"Simpson FR, et al. An examination of whether diabetes control and treatments are associated with change in frailty index across 8 years: an ancillary exploratory study from the Action for Health in Diabetes (Look AHEAD) Trial. Diabetes Care. 2022;46(3):519\u201325.","journal-title":"Diabetes Care"},{"issue":"10","key":"1049_CR13","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.jamda.2016.04.021","volume":"17","author":"N Veronese","year":"2016","unstructured":"Veronese N, et al. Frailty is associated with an increased risk of incident type 2 diabetes in the elderly. J Am Med Dir Assoc. 2016;17(10):902\u20137.","journal-title":"J Am Med Dir Assoc"},{"issue":"4","key":"1049_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.14336\/AD.2014.1022","volume":"6","author":"AH Abdelhafiz","year":"2015","unstructured":"Abdelhafiz AH, Sinclair AJ. Low HbA1c and Increased mortality risk\u2014is frailty a confounding factor? Aging Dis. 2015;6(4):262\u201370.","journal-title":"Aging Dis"},{"key":"1049_CR15","doi-asserted-by":"crossref","unstructured":"Pansini A, et al. Hyperglycemia and physical impairment in frail hypertensive older adults. Front Endocrinol. 2022;13:831556.","DOI":"10.3389\/fendo.2022.831556"},{"key":"1049_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cells10082115","author":"P Mone","year":"2021","unstructured":"Mone P, et al. Cognitive impairment in frail hypertensive elderly patients: role of hyperglycemia. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10082115.","journal-title":"Cells"},{"issue":"9","key":"1049_CR17","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s40520-022-02142-8","volume":"34","author":"AJ Sinclair","year":"2022","unstructured":"Sinclair AJ, Pennells D, Abdelhafiz AH. Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus\u2014a choice determined by metabolic phenotype. Aging Clin Exp Res. 2022;34(9):1949\u201367.","journal-title":"Aging Clin Exp Res"},{"issue":"1","key":"1049_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.clnu.2019.10.007","volume":"39","author":"G Bahat","year":"2020","unstructured":"Bahat G, \u0130lhan B, Karan MA. The concept of frailty should not be limited to malnutrition. Clin Nutr. 2020;39(1):325.","journal-title":"Clin Nutr"},{"issue":"1","key":"1049_CR19","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/s12916-022-02596-7","volume":"20","author":"K Jayanama","year":"2022","unstructured":"Jayanama K, et al. Relationship of body mass index with frailty and all-cause mortality among middle-aged and older adults. BMC Med. 2022;20(1):404.","journal-title":"BMC Med"},{"key":"1049_CR20","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1016\/j.clnu.2022.09.005","volume":"41","author":"S Ozkok","year":"2022","unstructured":"Ozkok S, et al. Sarcopenic obesity versus sarcopenia alone with the use of probable sarcopenia definition for sarcopenia: associations with frailty and physical performance. Clin Nutr. 2022;41(11):2509\u201316.","journal-title":"Clin Nutr"},{"key":"1049_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/17843286.2022.2075180","volume":"78","author":"G Bahat","year":"2023","unstructured":"Bahat G, et al. Associations between obesity, self-reported weakness and their combinations with mortality in nursing home residents. Acta Clin Belg. 2023;78(2):112\u201321.","journal-title":"Acta Clin Belg"},{"issue":"1","key":"1049_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.mcna.2017.08.007","volume":"102","author":"JA Batsis","year":"2018","unstructured":"Batsis JA, Zagaria AB. Addressing obesity in aging patients. Med Clin North Am. 2018;102(1):65\u201385.","journal-title":"Med Clin North Am"},{"issue":"5","key":"1049_CR23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/13685538.2018.1530208","volume":"23","author":"G Bahat","year":"2020","unstructured":"Bahat G, et al. Fat percentage cutoff values to define obesity and prevalence of sarcopenic obesity in community-dwelling older adults in Turkey. Aging Male. 2020;23(5):477\u201382.","journal-title":"Aging Male"},{"issue":"4","key":"1049_CR24","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.clnu.2022.01.024","volume":"41","author":"D Volkert","year":"2022","unstructured":"Volkert D, et al. ESPEN practical guideline: clinical nutrition and hydration in geriatrics. Clin Nutr. 2022;41(4):958\u201389.","journal-title":"Clin Nutr"},{"issue":"1","key":"1049_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.archger.2011.04.019","volume":"54","author":"G Bahat","year":"2012","unstructured":"Bahat G, et al. Which body mass index (BMI) is better in the elderly for functional status? Arch Gerontol Geriat. 2012;54(1):78\u201381.","journal-title":"Arch Gerontol Geriat"},{"issue":"5","key":"1049_CR26","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/geronb\/gbs067","volume":"67","author":"ME Bowen","year":"2012","unstructured":"Bowen ME. The relationship between body weight, frailty, and the disablement process. J Gerontol: Series B. 2012;67(5):618\u201326.","journal-title":"J Gerontol: Series B"},{"issue":"10","key":"1049_CR27","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1002\/oby.21612","volume":"24","author":"FW Cheng","year":"2016","unstructured":"Cheng FW, et al. Body mass index and all-cause mortality among older adults. Obesity (Silver Spring). 2016;24(10):2232\u20139.","journal-title":"Obesity (Silver Spring)"},{"issue":"8","key":"1049_CR28","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1001\/archinte.167.8.774","volume":"167","author":"S Al Snih","year":"2007","unstructured":"Al Snih S, et al. The effect of obesity on disability vs mortality in older Americans. Arch Intern Med. 2007;167(8):774\u201380.","journal-title":"Arch Intern Med"},{"issue":"8","key":"1049_CR29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","volume":"145","author":"AM Shaman","year":"2022","unstructured":"Shaman AM, et al. Effect of the Glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation. 2022;145(8):575\u201385.","journal-title":"Circulation"},{"issue":"1","key":"1049_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2021.102382","volume":"16","author":"MMY Lee","year":"2022","unstructured":"Lee MMY, et al. Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a meta-analysis with the FREEDOM cardiovascular outcomes trial. Diabetes Metab Syndr Clin Res Rev. 2022;16(1): 102382.","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"issue":"2","key":"1049_CR31","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148\u201358.","journal-title":"JAMA Cardiol"},{"issue":"7","key":"1049_CR32","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1111\/dom.14374","volume":"23","author":"D Giugliano","year":"2021","unstructured":"Giugliano D, et al. Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis. Diabetes Obes Metab. 2021;23(7):1672\u20136.","journal-title":"Diabetes Obes Metab"},{"issue":"18","key":"1049_CR33","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","volume":"81","author":"M Kittleson Michelle","year":"2023","unstructured":"Kittleson Michelle M, et al. 2023 ACC Expert Consensus Decision pathway on management of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2023;81(18):1835\u201378.","journal-title":"J Am Coll Cardiol"},{"key":"1049_CR34","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1\u2013127.","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"1049_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108737","volume":"174","author":"T Karagiannis","year":"2021","unstructured":"Karagiannis T, et al. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2021;174: 108737.","journal-title":"Diabetes Res Clin Pract"},{"issue":"18","key":"1049_CR36","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895\u20131032.","journal-title":"Circulation"},{"issue":"6","key":"1049_CR37","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40266-021-00855-5","volume":"38","author":"G Bahat","year":"2021","unstructured":"Bahat G, et al. International Validation of the Turkish Inappropriate Medication Use in the Elderly (TIME) criteria set: a Delphi Panel study. Drugs Aging. 2021;38(6):513\u201321.","journal-title":"Drugs Aging"},{"issue":"3","key":"1049_CR38","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s41999-020-00297-z","volume":"11","author":"G Bahat","year":"2020","unstructured":"Bahat G, et al. Turkish inappropriate medication use in the elderly (TIME) criteria to improve prescribing in older adults: TIME-to-STOP\/TIME-to-START. Eur Geriatr Med. 2020;11(3):491\u20138.","journal-title":"Eur Geriatr Med"},{"key":"1049_CR39","unstructured":"Perkovic V, Badve SV, Bakris GL. Treatment of diabetic kidney disease. https:\/\/www.uptodate.com\/contents\/treatment-of-diabetic-kidney-disease\/print. Accessed 11 May 2023."},{"issue":"12","key":"1049_CR40","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: improving global outcomes (KDIGO). Diabetes Care. 2022;45(12):3075\u201390.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"1049_CR41","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc23-S010","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, et al. 10. Cardiovascular disease and risk management: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S158-s190.","journal-title":"Diabetes Care"},{"issue":"1","key":"1049_CR42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.dld.2020.08.021","volume":"53","author":"J Kumar","year":"2021","unstructured":"Kumar J, et al. Antidiabetic drugs and non-alcoholic fatty liver disease: a systematic review, meta-analysis and evidence map. Dig Liver Dis. 2021;53(1):44\u201351.","journal-title":"Dig Liver Dis"},{"issue":"2","key":"1049_CR43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/metabo11020087","volume":"11","author":"Z Szekeres","year":"2021","unstructured":"Szekeres Z, Toth K, Szabados E. The effects of SGLT2 inhibitors on lipid metabolism. Metabolites. 2021;11(2):87.","journal-title":"Metabolites"},{"issue":"1","key":"1049_CR44","doi-asserted-by":"publisher","first-page":"24263","DOI":"10.1038\/s41598-021-03773-z","volume":"11","author":"L Cheng","year":"2021","unstructured":"Cheng L, et al. Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome. Sci Rep. 2021;11(1):24263.","journal-title":"Sci Rep"},{"issue":"3","key":"1049_CR45","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11906-022-01170-z","volume":"24","author":"LY Herat","year":"2022","unstructured":"Herat LY, et al. Targeting features of the metabolic syndrome through sympatholytic effects of SGLT2 inhibition. Curr Hypertens Rep. 2022;24(3):67\u201374.","journal-title":"Curr Hypertens Rep"},{"issue":"10","key":"1049_CR46","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrneph.2017.123","volume":"13","author":"MHA Muskiet","year":"2017","unstructured":"Muskiet MHA, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol. 2017;13(10):605\u201328.","journal-title":"Nat Rev Nephrol"},{"key":"1049_CR47","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s11325-022-02594-2","volume":"27","author":"BS Wojeck","year":"2023","unstructured":"Wojeck BS, et al. Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. Sleep Breath. 2023;27(2):669\u201372.","journal-title":"Sleep Breath"},{"issue":"1","key":"1049_CR48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11325-022-02606-1","volume":"27","author":"C Tanriover","year":"2023","unstructured":"Tanriover C, et al. Potential Use of SGLT-2 inhibitors in obstructive sleep apnea: a new treatment on the horizon. Sleep Breath. 2023;27(1):77\u201389.","journal-title":"Sleep Breath"},{"issue":"1","key":"1049_CR49","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.clnu.2019.10.010","volume":"39","author":"G Bahat","year":"2020","unstructured":"Bahat G, Erdogan T, Karan MA. Need for increased awareness for avoiding metformin treatment in malnourished older adults with diabetes mellitus. Clin Nutr. 2020;39(1):322.","journal-title":"Clin Nutr"},{"issue":"Suppl 1","key":"1049_CR50","first-page":"S144","volume":"45","author":"Cardiovascular Disease and Risk Management","year":"2022","unstructured":"Cardiovascular Disease and Risk Management. Standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S144-s174.","journal-title":"Diabetes Care"},{"issue":"5","key":"1049_CR51","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1210\/jc.2019-00198","volume":"104","author":"D LeRoith","year":"2019","unstructured":"LeRoith D, et al. Treatment of diabetes in older adults: an Endocrine Society* Clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1520\u201374.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1049_CR52","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/17843286.2021.1952379","volume":"77","author":"G Bahat","year":"2022","unstructured":"Bahat G, et al. Management of type 2 diabetes mellitus in older adults: eight case studies with focus SGLT-2 inhibitors and metformin. Acta Clin Belg. 2022;77(4):727\u201334.","journal-title":"Acta Clin Belg"},{"issue":"5","key":"1049_CR53","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2337\/dc21-2434","volume":"45","author":"P Mone","year":"2022","unstructured":"Mone P, et al. Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction. Diabetes Care. 2022;45(5):1247\u201351.","journal-title":"Diabetes Care"},{"issue":"8","key":"1049_CR54","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1161\/HYPERTENSIONAHA.122.19586","volume":"79","author":"P Mone","year":"2022","unstructured":"Mone P, et al. SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients. Hypertension. 2022;79(8):1633\u201343.","journal-title":"Hypertension"},{"key":"1049_CR55","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/DMSO.S71923","volume":"8","author":"DF Kruger","year":"2015","unstructured":"Kruger DF, LaRue S, Estepa P. Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment. Diabetes Metab Syndr Obes. 2015;8:49\u201356.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"1049_CR56","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12933-023-01786-8","volume":"22","author":"F Rea","year":"2023","unstructured":"Rea F, et al. Adherence to antidiabetic drug therapy and reduction of fatal events in elderly frail patients. Cardiovasc Diabetol. 2023;22(1):53.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"1049_CR57","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2337\/dc14-0649","volume":"38","author":"F Porcellati","year":"2014","unstructured":"Porcellati F, et al. Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. Diabetes Care. 2014;38(3):503\u201312.","journal-title":"Diabetes Care"},{"issue":"1","key":"1049_CR58","first-page":"10","volume":"7","author":"AJ Sinclair","year":"2018","unstructured":"Sinclair AJ, et al. An international position statement on the management of frailty in diabetes mellitus: summary of recommendations 2017. J Frailty Aging. 2018;7(1):10\u201320.","journal-title":"J Frailty Aging"},{"issue":"10","key":"1049_CR59","doi-asserted-by":"publisher","first-page":"851","DOI":"10.2165\/00002512-200724100-00005","volume":"24","author":"D Cayea","year":"2007","unstructured":"Cayea D, Boyd C, Durso SC. Individualising therapy for older adults with diabetes mellitus. Drugs Aging. 2007;24(10):851\u201363.","journal-title":"Drugs Aging"},{"key":"1049_CR60","doi-asserted-by":"publisher","unstructured":"By the American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023. https:\/\/doi.org\/10.1111\/jgs.18372.","DOI":"10.1111\/jgs.18372"},{"key":"1049_CR61","doi-asserted-by":"crossref","unstructured":"Dong B, et al. The extraglycemic effect of sglt-2is on mineral and bone metabolism and bone fracture. Front Endocrinol. 2022;13:918350.","DOI":"10.3389\/fendo.2022.918350"},{"issue":"7","key":"1049_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3170","volume":"35","author":"X Li","year":"2019","unstructured":"Li X, et al. Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: an updated meta-analysis. Diabetes Metab Res Rev. 2019;35(7): e3170.","journal-title":"Diabetes Metab Res Rev"},{"key":"1049_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art. Mol Metab. 2021;46: 101102.","journal-title":"Mol Metab"},{"issue":"19","key":"1049_CR64","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Eng J Med. 2016;375(19):1834\u201344.","journal-title":"N Eng J Med"},{"issue":"9","key":"1049_CR65","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.2337\/dc22-0338","volume":"45","author":"A Celli","year":"2022","unstructured":"Celli A, et al. Lifestyle intervention strategy to treat diabetes in older adults: a randomized controlled trial. Diabetes Care. 2022;45(9):1943\u201352.","journal-title":"Diabetes Care"},{"issue":"4","key":"1049_CR66","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.clnu.2021.11.014","volume":"41","author":"LM Donini","year":"2022","unstructured":"Donini LM, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Clin Nutr. 2022;41(4):990\u20131000.","journal-title":"Clin Nutr"},{"key":"1049_CR67","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s41999-022-00674-w","volume":"13","author":"G Bahat","year":"2022","unstructured":"Bahat G. Sarcopenic obesity: a hot yet under considered evolving concept. Eur Geriatr Med. 2022;13(5):1023\u20134.","journal-title":"Eur Geriatr Med"},{"issue":"7","key":"1049_CR68","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/ggi.13668","volume":"19","author":"G Bahat","year":"2019","unstructured":"Bahat G, et al. Association of different bioimpedanciometry estimations of muscle mass with functional measures. Geriatr Gerontol Int. 2019;19(7):593\u20137.","journal-title":"Geriatr Gerontol Int"},{"key":"1049_CR69","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.eurger.2015.12.012","volume":"7","author":"G Bahat","year":"2016","unstructured":"Bahat G, Ilhan B. Sarcopenia and the cardiometabolic syndrome: a narrative review. Eur Geriatr Med. 2016;7:220\u20133.","journal-title":"Eur Geriatr Med"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-023-01049-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-023-01049-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-023-01049-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T17:25:20Z","timestamp":1702747520000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-023-01049-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1049"],"URL":"https:\/\/doi.org\/10.1007\/s40266-023-01049-x","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]},"assertion":[{"value":"26 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Gulistan Bahat, Serdar Ozkok, and Mirko Petrovic declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"GB: conceptualization, methodology, writing (reviewing and editing); SO: investigation, writing (original draft preparation as well as reviewing and editing); MP: writing (reviewing and editing).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"Data sharing is not applicable to this article, as no datasets were generated or analyzed during the current study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}